Key Highlights
- SLXN reported a Q3 net loss of US$2,533 thousand versus US$3,262 thousand a year earlier.
- The first patient was dosed in the SIL204 Phase 2/3 trial on September 30, 2026.
- Cash and cash equivalents totaled US$4.8 million at September 30, 2026.
- The company disclosed substantial doubt about its ability to continue as a going concern.
SLXN filed its Quarterly Report on November 12, 2026, for the three and nine months ended September 30, 2026. Research and Development expenses were US$1,286 thousand, versus US$2,157 thousand, a decrease of 40.9%. The company attributed the decrease primarily to US$0.8 million lower subcontractor and consultant costs, because the third quarter of 2025 included production of a non-GMP API batch with no corresponding cost in 2026.
The company said third-quarter 2026 research expenses primarily related to initiation of its Phase 2/3 clinical trial for SIL204, in which the first patient was dosed on September 30, 2026. General and administrative expenses were US$1,398 thousand, versus US$1,135 thousand, an increase of 27.3%, which the company tied to US$0.4 million of higher professional services costs, including legal, consultants and public company costs.
Net Loss and Nine-Month Results
Total operating expenses were US$2,684 thousand versus US$3,292 thousand, and the operating loss equaled those amounts. Financial income, net, was US$151 thousand versus US$30 thousand. Net loss was US$2,533 thousand versus US$3,262 thousand.
For the nine months, research and development expenses were US$4,868 thousand versus US$3,765 thousand, an increase of 28.9%, which the company tied to US$1.0 million of higher subcontractor and consultant expenses for toxicology studies, product development, GMP manufacturing, regulatory approval and contract research organization setup. General and administrative expenses were US$4,245 thousand versus US$3,461 thousand. Net financial income was US$296 thousand versus net financial expense of US$271 thousand. Net loss was US$8,817 thousand versus US$7,500 thousand.
Financing Activity, Cash and Going Concern Disclosure
Cash and cash equivalents totaled US$4.8 million at September 30. The company described registered public offerings in January 2025, September 2025 and August 2026, and induced Warrant exercise transactions in January 2025, August 2025, May 2026 and September 2026. Under its at-the-market agreement with H.C. Wainwright, which provides for sales of up to US$13.17 million of ordinary shares, it raised approximately US$0.08 million, US$1.9 million and US$1.8 million, net of fees, in the first, second and third quarters of 2026, and US$0.05 million after quarter end. About US$9.2 million remained available as of the filing date.
The company said its current cash and cash equivalents and anticipated Cash Flow from operations are not sufficient to meet cash requirements for the next 12 months, but only for several months from the filing date, and that it needs to raise additional capital. It described substantial doubt about its ability to continue as a going concern in the notes to its financial statements.
Quarter in Review: Trial Initiation, Spending and Funding Needs
SLXN's third quarter combined lower research spending and a net loss of US$2,533 thousand with the first patient dosed in the SIL204 Phase 2/3 trial. The company said its Capital requirements depend on the scale and pace of those trials and on spending for further development of SIL204, additional pipeline products and hiring.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...